Androgen associated hepatocellular carcinoma with an aggressive course
- D Gleeson 1, M J Newbould , P Taylor , R F McMahon , B C Leahy , T W Warnes
- 1Department of Gastroenterology, Royal Infirmary, Manchester.
- 0Department of Gastroenterology, Royal Infirmary, Manchester.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hepatocellular carcinomas from androgen treatment usually have a benign outcome. However, one patient experienced an aggressive, fatal cancer after 24 years of androgen therapy, challenging this notion.
Area Of Science
- Hepatology
- Oncology
- Endocrinology
Background
- Androgen treatment is associated with hepatocellular carcinoma (HCC) development.
- Previously, these tumors were considered to have a benign clinical outcome.
Observation
- A case study of a male patient undergoing androgen treatment for 24 years.
- Development of hepatocellular carcinoma after prolonged androgen exposure.
Findings
- The patient's tumor initially showed partial regression upon androgen withdrawal.
- Subsequently, the tumor exhibited an aggressive and ultimately fatal clinical course, contradicting previous observations.
Implications
- This case challenges the established understanding of the clinical behavior of androgen-associated HCC.
- Highlights the need for careful monitoring and consideration of aggressive treatment strategies in select cases.
- Suggests potential variability in tumor response and progression despite androgen treatment.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.